166 related articles for article (PubMed ID: 24619762)
1. p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
Xie Y; Bulbul MA; Ji L; Inouye CM; Groshen SG; Tulpule A; O'Malley DP; Wang E; Siddiqi IN
Am J Clin Pathol; 2014 Apr; 141(4):593-604. PubMed ID: 24619762
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
3. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
[TBL] [Abstract][Full Text] [Related]
4. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
[TBL] [Abstract][Full Text] [Related]
5. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
Barrans S; Crouch S; Smith A; Turner K; Owen R; Patmore R; Roman E; Jack A
J Clin Oncol; 2010 Jul; 28(20):3360-5. PubMed ID: 20498406
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
7. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
[TBL] [Abstract][Full Text] [Related]
8. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
Gualco G; Weiss LM; Barber GN; Bacchi CE
Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of mTOR in germinal center and nongerminal center group of diffuse large B-cell lymphoma: a clinicopathological study.
Vajpayee N; Burack R; Wang D; Hutchison RE; Gajra A
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):159-63. PubMed ID: 25458080
[TBL] [Abstract][Full Text] [Related]
10. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
Bouroumeau A; Bussot L; Bonnefoix T; Fournier C; Chapusot C; Casasnovas O; Martin L; McLeer A; Col E; David-Boudet L; Lefebvre C; Algrin C; Raskovalova T; Jacob MC; Vettier C; Chevalier S; Callanan MB; Gressin R; Emadali A; Sartelet H
J Pathol Clin Res; 2021 Nov; 7(6):604-615. PubMed ID: 34374220
[TBL] [Abstract][Full Text] [Related]
11. p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.
Richardson AI; Zhang D; Woodroof J; Cui W
Hum Pathol; 2019 Apr; 86():21-31. PubMed ID: 30496802
[TBL] [Abstract][Full Text] [Related]
12. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
13. [Effect of P53 Expression on Prognosis of Patients with Double Expressor Lymphoma].
Ding X; Hou SL; Li YQ; Li X; Li L; Lian K; Wang GG; Wu XB; Zhang ZH; Liu H; Wang YQ; Zhang QH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1504-1514. PubMed ID: 31607305
[TBL] [Abstract][Full Text] [Related]
14. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
Wang XJ; L Jeffrey Medeiros ; Bueso-Ramos CE; Tang G; Wang S; Oki Y; Desai P; Khoury JD; Miranda RN; Tang Z; Reddy N; Li S
Mod Pathol; 2017 Feb; 30(2):194-203. PubMed ID: 27739436
[TBL] [Abstract][Full Text] [Related]
15. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
[TBL] [Abstract][Full Text] [Related]
16. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
17. [Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases].
Zhou J; Xia C; Shen Q; Yin H; Zhang X; Shi Q; Zhou X; Ma J
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):8-14. PubMed ID: 24713242
[TBL] [Abstract][Full Text] [Related]
18. [Significance of BCL6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma].
Gao P; Li Q; Wang Z; Yan F; Lu C; Cao X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Oct; 31(5):628-31. PubMed ID: 25297597
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.
Kramer MH; Hermans J; Parker J; Krol AD; Kluin-Nelemans JC; Haak HL; van Groningen K; van Krieken JH; de Jong D; Kluin PM
J Clin Oncol; 1996 Jul; 14(7):2131-8. PubMed ID: 8683246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
